logo
Delcath Systems Issues Full Year 2025 Guidance

Delcath Systems Issues Full Year 2025 Guidance

Business Wire22-05-2025

QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH) ('Delcath' or the 'Company'), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced full year 2025 financial guidance and its intention to enter into a Medicaid National Drug Rebate Agreement (NDRA) to expand patient access.
2025 Full Year Financial Guidance
The Company's financial outlook for fiscal year 2025 is as follows:
Total CHEMOSAT and HEPZATO KIT revenue of $94 to $98 million, an increase of more than 150% over 2024
Gross margins between 83% to 85%
Positive adjusted EBITDA and cashflow in each quarter of 2025
National Medicaid Drug Rebate Agreement
Delcath will participate in the Medicaid Drug Rebate Program, which entails providing Medicaid rebates and 340B discounts to eligible entities. The Company has initiated the process of entering into the NDRA with the Centers for Medicare and Medicaid Services and expects it to take effect at the beginning of the third quarter of 2025.
'Our decision to enter into the NDRA simplifies Medicaid access and enables eligible hospitals to access 340B drug pricing. We believe this will expand treatment availability and accelerate adoption of HEPZATO in the United States,' said Gerard Michel, Chief Executive Officer of Delcath. 'Based on current center activation rates and rising utilization, we expect total HEPZATO treatment volume in 2025 to increase at least 200% versus 2024.'
About Delcath Systems, Inc., HEPZATO KIT and CHEMOSAT
Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The company's proprietary products, HEPZATO KIT™ (HEPZATO (melphalan) for Injection/Hepatic Delivery System) and CHEMOSAT ® Hepatic Delivery System for Melphalan percutaneous hepatic perfusion (PHP), are designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects during a PHP procedure.
In the United States, HEPZATO KIT is considered a combination drug and device product and is regulated and approved for sale as a drug by the FDA. HEPZATO KIT is comprised of the chemotherapeutic drug melphalan and Delcath's proprietary Hepatic Delivery System (HDS). The HDS is used to isolate the hepatic venous blood from the systemic circulation while simultaneously filtrating hepatic venous blood during melphalan infusion and washout. The use of the HDS results in loco-regional delivery of a relatively high melphalan dose, which can potentially induce a clinically meaningful tumor response with minimal hepatotoxicity and reduce systemic exposure. HEPZATO KIT is approved in the United States as a liver-directed treatment for adult patients with metastatic uveal melanoma (mUM) with unresectable hepatic metastases affecting less than 50% of the liver and no extrahepatic disease, or extrahepatic disease limited to the bone, lymph nodes, subcutaneous tissues, or lung that is amenable to resection or radiation. Please see the full Prescribing Information, including BOXED WARNING for the HEPZATO KIT.
In Europe, the device-only configuration of the HDS is regulated as a Class III medical device and is approved for sale under the trade name CHEMOSAT Hepatic Delivery System for Melphalan, or CHEMOSAT, where it has been used in the conduct of percutaneous hepatic perfusion procedures at major medical centers to treat a wide range of cancers of the liver.
Safe Harbor / Forward-Looking Statements
The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by the Company or on its behalf. This press release contains forward-looking statements, including the Company's 2025 financial outlook, which are subject to certain risks and uncertainties, that can cause actual results to differ materially from those described. The words 'anticipate,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'target,' 'will,' 'would' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Factors that may cause such differences include, but are not limited to, uncertainties relating to: the Company's ability to successfully enter into the NDRA and its potential impact on the Company's business and operation; the Company's commercialization plans and its ability to successfully commercialize the HEPZATO KIT; the Company's successful management of the HEPZATO KIT supply chain, including securing adequate supply of critical components necessary to manufacture and assemble the HEPZATO KIT; successful FDA inspections of the facilities of the Company and those of its third-party suppliers/manufacturers; the Company's successful implementation and management of the HEPZATO KIT Risk Evaluation and Mitigation Strategy; the potential benefits of the HEPZATO KIT as a treatment for patients with primary and metastatic disease in the liver; the Company's ability to obtain reimbursement for the HEPZATO KIT; and the Company's ability to successfully enter into any necessary purchase and sale agreements with users of the HEPZATO KIT. For additional information about these factors, and others that may impact the Company, please see the Company's filings with the Securities and Exchange Commission, including those on Forms 10-K, 10-Q, and 8-K. However, new risk factors and uncertainties may emerge from time to time, and it is not possible to predict all risk factors and uncertainties. Accordingly, you should not place undue reliance on these forward-looking statements, which speak only as of the date they are made. We undertake no obligation to publicly update or revise these forward-looking statements to reflect events or circumstances after the date they are made.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

New Logitech Flip Folio Keeps Up with Your Every Move
New Logitech Flip Folio Keeps Up with Your Every Move

Business Wire

time39 minutes ago

  • Business Wire

New Logitech Flip Folio Keeps Up with Your Every Move

LAUSANNE, Switzerland & SAN JOSE, Calif.--(BUSINESS WIRE)--Logitech (SIX: LOGN) (NASDAQ: LOGI) today announced the Flip Folio, a protective case with a magnetically-storable keyboard for iPad Pro and iPad Air, designed to keep up with your lifestyle, whether you're enjoying videos, creative projects, or just collaborating. Unlike existing keyboard cases for iPad, this full-size Bluetooth keyboard, with a compact design, allows for flexibility, letting you position your set-up exactly how you like. 'We've designed Flip Folio to make the iPad experience both fun and functional, helping you stay focused on what matters,' said Joseph Mingori, GM of mobile and audio solutions at Logitech. 'Flip Folio enhances everyday experiences–from binge watching to checking your social media or emails– by delivering portability and connectivity, setting people free so they can do what they love from anywhere.' When not in use, the keyboard magnetically snaps to the back of the case for hassle-free storage. It also provides front and back protection for your iPad–perfect when you're on the move, tucking it under your arm, or slipping it into your bag. With the ability to pair multiple devices, you can easily switch between your iPad, phone, or other Bluetooth -enabled devices, ensuring seamless connectivity across your ecosystem with Flip Folio. Designed for Sustainability Flip Folio is designed with sustainability in mind, featuring a minimum of 37% certified post-consumer recycled plastic for the Graphite and Midnight Black models, giving a second life to end-of-use plastics. The aluminum is produced using low-carbon processes, and all paper packaging is responsibly sourced from FSC™-certified and controlled sources. Tech Specs Stowable Keyboard: Bluetooth keyboard with magnetic attachment for storage Protection: Front and back iPad protection Adjustability: Multi-angle kickstand (with a compact footprint) Connectivity: Multi-device pairing, Easy-switch between 3 devices iPad Orientation: Landscape and portrait Compatibility: iPad Pro (11-inch M4, 13-inch M4) and iPad Air (11-inch M2 & M3, 13-inch M2 & M3, and 5th Gen) Pricing and availability Flip Folio is priced at $179.99/€199 for 13-inch iPad Pro and iPad Air models, and $159.99/€179 for 11-inch iPad Pro and iPad Air models. Available in a range of stylish colors, outlined below: For more details, please visit or check with your local or online retailer About Logitech Logitech designs software-enabled hardware solutions that help businesses thrive and bring people together when working, creating, gaming and streaming. As the point of connection between people and the digital world, our mission is to extend human potential in work and play, in a way that is good for people and the planet. Founded in 1981, Logitech International is a Swiss public company listed on the SIX Swiss Exchange (LOGN) and on the Nasdaq Global Select Market (LOGI). Find Logitech and its other brands, including Logitech G, at or company blog. Logitech and other Logitech marks are trademarks or registered trademarks of Logitech Europe S.A. and/or its affiliates in the U.S. and other countries. All other trademarks are the property of their respective owners. For more information about Logitech and its products, visit the company's website at

Aera Technology Advances People-Centric Decision Intelligence with Agentic AI
Aera Technology Advances People-Centric Decision Intelligence with Agentic AI

Business Wire

time40 minutes ago

  • Business Wire

Aera Technology Advances People-Centric Decision Intelligence with Agentic AI

LONDON--(BUSINESS WIRE)--Today at AeraHUB 25 London, the premier decision intelligence summit, Aera Technology will announce a major release of its industry-leading Aera Decision Cloud™, introducing a new wave of Agentic AI capabilities that empower users across roles and experience levels to harness AI to make smarter, faster decisions at scale. 'Aera Decision Cloud is the only platform that unifies the full decision-making context — blending structured and unstructured enterprise data, human expertise, and the reasoning capabilities of large language models." Fred Laluyaux, CEO, Aera Technology Share With this release, Aera Technology expands the frontier of people-centric decision intelligence. From the frontlines to the back office, any users can now tap the power of agents to build Aera Skills™ decision logic with natural language prompting — expanding decision-making use cases and unlocking value. A new AI-powered Data Wizard also allows data to be uploaded and categorized in seconds, and an enhanced Aera Chat interface delivers real-time insights, bringing the power of AI-driven decision-making directly into users' hands. 'Aera Decision Cloud is the only platform that unifies the full decision-making context — blending structured and unstructured enterprise data, human expertise, and the reasoning capabilities of large language models,' said Fred Laluyaux, Co-Founder, President, and CEO of Aera Technology. 'By putting these advanced capabilities directly in the hands of users, we're helping organizations achieve new levels of speed and agility in an increasingly complex world.' Meeting the Moment: AI for Today's Enterprise Challenges This comes at a pivotal time, when the speed and precision of decision execution can determine business success — and organizations face ongoing talent shortages, reskilling needs and increasing pressure to achieve tangible outcomes using AI technologies. Aera Technology's latest release redefines how decisions are made. By placing humans — regardless of technical expertise — at the center of creating AI-powered decision flows, Aera enables a shift from people doing data analysis to people architecting decision automation and overseeing action. This shift empowers business experts to increase their productivity and strategic impact. Key Innovations Rapid Skill Creation: Build Aera Skills™ with embedded AI agents that reason and act based on natural language instructions with built-in guardrails that ensure transparency, accountability, and governance. Any Data, Any Format: Tap into both structured and unstructured data sources — from transactional systems to PDFs and emails — to inform context-rich decisions. Enhanced Aera Cha t: Ask complex, data-driven questions in natural language and receive precise, actionable answers — with execution capabilities built directly into the chat. Smart Data Wizard: Upload data in seconds. The Data Wizard automatically classifies and prepares it for use — no technical training required. Key Benefits Data-Ready from Any Source: Seamlessly integrates structured and unstructured data — from systems, documents, and emails — to automate complex processes like claims management, procurement negotiations, and contract compliance. From Coding to Prompting: Accelerates time to value by defining decision intent in natural language. Agentic AI handles reasoning and generates decision logic. Autonomous, Scalable Collaboration: Communicates and coordinates across people, systems, and vendors, automating decision processes, such as negotiating order modifications. Fast Time to Action: Detects decision triggers, simulates alternatives, and executes actions autonomously. Join Us and See it in Action AeraHUB 25 London: The Decision Intelligence Summit June 11, 2025 | The Brewery, 52 Chiswell Street, London View the session lineup Learn more about Aera agentic decision intelligence Follow Aera Technology on LinkedIn for live updates and insights from the event. About Aera Technology Aera Technology, the decision intelligence company, created Aera, the first decision intelligence agent. Real-time and always-on, Aera understands how a business works, makes actionable recommendations, predicts business outcomes, executes decisions at scale, and learns from every decision. Supporting the full spectrum of decisions, from operational to strategic, Aera is powered by Aera Decision Cloud™ and its composable Aera Skills™. By empowering the world's leading companies to optimize decisions across the value chain, Aera is enabling a more sustainable, intelligent, and efficient world. Learn more at

Panel held to discuss possible cuts to Medicaid
Panel held to discuss possible cuts to Medicaid

Yahoo

timean hour ago

  • Yahoo

Panel held to discuss possible cuts to Medicaid

(COLORADO SPRINGS) — Local health care workers and Democrats held a panel on Tuesday, June 10 discussing how Medicaid budget cuts could impact Colorado Springs. Data shows 19% of the 5th Congressional District, which covers most of El Paso County, are enrolled in Medicaid. Organizers of the panel said that number could drop if President Donald Trump signs his so-called 'Big Beautiful Bill.' The bill adds restrictions to who would be eligible for Medicaid, which Republicans argue would cut down on fraud. However, those at the panel on Tuesday disagree, arguing these cuts will impact services across the board. They said the only way to make sure your voice is heard is to speak up to the lawmakers who represent you. 'Call your representatives. There is somebody, they ain't going to answer the phone, but there is somebody who can answer the phone. Get out. Speak your mind. Talk to your neighbor. Find out what goes on,' said Leeann Webster with CA Home Health Care. The senate is currently debating the controversial bill. Both Colorado Senators John Hickenlooper and Michael Bennett both indicated they will not vote in favor of the measure. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store